A Chinese medicine formula(Sanzi-huangshi pill) as an adjuvant therapy for lower-risk myelodysplastic syndrome: protocol for a prospective, randomized, open-label, blinded-endpoint (PROBE) trial

Abstract

Abstract Background: Lower-risk myelodysplastic syndrome (MDS) is characterized by the presence of dysplasia, low bone marrow blast percentage, low number and depth of cytopenia(s), and relatively good-risk karyotpic and molecular abnormalities. Lower-risk MDS patients have primarily received supportive care, immunomodulators, and immunosuppressants. New effective regimens or drugs are urgently needed for the treatment of lower-risk MDS owing to the unsatisfactory clinical efficacy. Sanzi-huangshi pill is an arsenic-containing Chinese medicine that has been used as a promising drug for MDS for decades, but its efficacy has not yet been proven by high-quality clinical trial. Methods: SPIRIT guidelines were followed in drafting this protocol for a randomized controlled multicenter trial. Ninety-two adults with lower-risk MDS are randomly assigned in a 1:1 ratio to Sanzi-huangshi pill group or control group, and all participants are required to receive 6 months of intervention and 18 months of observation. The primary outcome is Overall Response Rate defined as the sum of complete remission, partial remission, cytogenetic complete remission and hematologic improvement accounting for the proportion of total evaluable cases. Discussion: This is the first randomized controlled trial to evaluate the efficacy and safety of arsenic-containing Chinese medicine as an adjuvant therapy in lower-risk MDS with serum erythropoietin (sEPO) >500 IU/ml. The purpose of this study is to correctly evaluate the position of traditional Chinese medicine in the treatment plan of MDS and to formulate an effective regimen of integrated Traditional Chinese and Western Medicine to provide preliminary clinical evidence. Clinical Trial Registration: http://www.chictr.org.cn, identifier: ChiCTR2200064230, Registered September 30, 2022.